BioWorld

Aug. 13, 2009

Seattle Genetics Gets $118.2M for Antibody Conjugate, More

In the wake of a stock bump following a $2.4 billion acquisition offer for fellow antibody firm Medarex Inc., Seattle Genetics Inc. is boosting its cash position by $118.2 million through a public stock offering. (BioWorld Today) Read More

Merrem Squeeze Helps Motivate AstraZeneca In Ceftaroline Deal

Late Gene Therapy Gain Chips Away at Critical Period Notion

Enzyme-Targeted Cancer Push Garners $17M for Constellation

Corrections & Clarifications

FDA: Experimental Therapy OK If Nothing Else Available

Other News To Note

Clinic Roundup

Appointments And Advancements

Today's news in brief

BioWorld

BioWorld briefs for June 5, 2026.

ASCO 2026: A revolution in pancreatic cancer

BioWorld

At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...

News in brief

BioWorld Asia

BioWorld Asia briefs for June 2, 2026

EASL 2026: Emerging liver disease targets to watch

BioWorld

At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...

Bispecific antibodies with heavy chain in green and pink, light chain in blue and yellow

ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out

BioWorld

Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...